Skip to main content
. 2015 Sep 30;10(1):3–17. doi: 10.1177/1753465815603659

Figure 4.

Figure 4.

Incremental cost in relation to the efficacy of Neurally Adjusted Ventilator Assist (NAVA) versus pressure support ventilation (PSV). The relation between the incremental cost (model output) and the absolute difference in proportion of asynchronous patients with asynchrony index (AI) at least 10% between PSV and NAVA (model input) is illustrated. The base case, with efficacy taken from Piquilloud and colleagues [Piquilloud et al. 2011] is indicated, and the results of the clinical studies applied in the sensitivity analyses are shown in the following order from the base case: [Terzi et al. 2010; Colomboet al. 2008; de la Oliva et al. 2012; Moereret al. 2008; Spahija et al. 2010; Cammarota et al. 2011]. In addition, four hypothetical scenarios were added, to illustrate breakeven; that is, at which point the difference in proportion of asynchronous patients with AI at least 10% between NAVA and PSV is so small that the additional cost of the NAVA catheter balances the gain from reducing the number of days on mechanical ventilation (MV). In this analysis, an absolute efficacy difference larger than 2.5% is needed in order for NAVA to be cost effective.